Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$54 Mln
Revenue (TTM)
$200 Mln
Net Profit (TTM)
$0 Mln
ROE
-20.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$-9.3
EPS
$-3.7
Face value
--
Shares outstanding
5,961,390
CFO
$-1,481.40 Mln
EBITDA
$-2,037.01 Mln
Net Profit
$-1,956.63 Mln
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
---|---|---|---|---|---|---|---|
Atara Biotherapeutics (ATRA)
| -40.3 | 18.0 | 11.7 | -19.5 | -62.2 | -50.4 | -40.2 |
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
---|---|---|---|---|---|---|---|
Atara Biotherapeutics (ATRA)
| 3.8 | -84.4 | -79.2 | -19.7 | 19.2 | -52.6 | 91.3 |
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics (ATRA)
|
7.9 | 54.0 | 199.7 | -15.6 | -5.3 | -- | -- | 2.0 |
49.9 | 7,861.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
128.2 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
147.5 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
53.0 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
40.4 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
52.8 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
309.4 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
25.9 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
126.6 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 5.0 |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy... program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Read more
President, CEO & Director
Dr. Pascal Touchon D.V.M.
President, CEO & Director
Dr. Anhco Nguyen Ph.D.
Headquarters
Thousand Oaks, CA
Website
The total asset value of Atara Biotherapeutics Inc (ATRA) stood at $ 110 Mln as on 31-Mar-25
The share price of Atara Biotherapeutics Inc (ATRA) is $7.94 (NASDAQ) as of 20-Jun-2025 16:00 EDT. Atara Biotherapeutics Inc (ATRA) has given a return of -62.18% in the last 3 years.
Atara Biotherapeutics Inc (ATRA) has a market capitalisation of $ 54 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Atara Biotherapeutics Inc (ATRA) is 1.97 times as on 20-Jun-2025, a 29% discount to its peers’ median range of 2.78 times.
Since, TTM earnings of Atara Biotherapeutics Inc (ATRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Atara Biotherapeutics Inc (ATRA) and enter the required number of quantities and click on buy to purchase the shares of Atara Biotherapeutics Inc (ATRA).
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
The CEO & director of Dr. Pascal Touchon D.V.M.. is Atara Biotherapeutics Inc (ATRA), and CFO & Sr. VP is Dr. Anhco Nguyen Ph.D..
There is no promoter pledging in Atara Biotherapeutics Inc (ATRA).
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
1,260
|
|
1,128
|
|
991
|
|
988
|
|
870
|
|
829
|
|
809
|
|
742
|
|
664
|
Atara Biotherapeutics Inc. (ATRA) | Ratios |
---|---|
Return on equity(%)
|
--
|
Operating margin(%)
|
-5.31
|
Net Margin(%)
|
-7.83
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Atara Biotherapeutics Inc (ATRA) was $0 Mln.